Amlodipine Besylate and Benazepril Capsules Recalled for Incorrect Expiration Date Label
Lupin Pharmaceuticals is recalling 7,668 bottles of Amlodipine Besylate and Benazepril Hydrochloride capsules distributed nationwide due to incorrect expiration dates on the label.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a minor labeling error with no reported illnesses or injuries. The hazard is theoretical—potential use of expired medication—rather than actual harm. Per the rubric, minor labeling errors are classified as Score 2 (Moderate).
Plain-English summary
Lupin Pharmaceuticals Inc. is recalling Amlodipine Besylate and Benazepril Hydrochloride Capsules USP 2.5 mg/10 mg (Lot GB01616) due to a labeling error. The bottles were released with an incorrect expiration date printed on the label.
The label shows an expiration date of February 28, 2027, but the correct expiration date is January 2027. This discrepancy could lead to patients using the medication beyond its actual shelf life if they rely on the printed expiration date.
The recall affects 7,668 bottles distributed nationwide. Patients should contact their pharmacist or physician if they have this medication to verify the correct expiration date. Healthcare providers and pharmacies should quarantine and remove affected bottles from stock.
The recalled product
- Product
- AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE (AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE)
- Brand
- AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE
- Manufacturer
- Lupin Pharmaceuticals Inc.
- Hazard
- incorrect-expiration-date
- mislabeling
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot GB01616
- expiration 2/28/2027
UPCs (1)
- 0368180459019
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27